Study validates tolerability of Lonza's ResistAid

Immune support ingredient from larch trees was very well tolerated by most subjects.

A new study shows that ResistAid™, Lonza’s proprietary immune ingredient, has very good tolerability. The double-blind, randomized, placebo-controlled clinical trial was published in the November issue of the Food and Nutrition Sciences (Vol. 3, No. 11, p. 1533-1538).

Conducted by analyze & realize AG, the study interviewed a total of 199 healthy participants, who received either 4.5g ResistAid or placebo for a 12 week period. To examine tolerability based on safety parameters, the research recorded the number of adverse events and changes in various clinical and laboratory parameters, as well as the global evaluation of tolerability by investigators and subjects, as compared to placebo.

“The tolerability was rated as “very good” or “good” by the investigators for 99 percent of the subjects, and by 98 percent of subjects in self-assessment with no statistical differences to placebo,” says Barbara Grube, MD, coordinating investigator and lead author of the study.

“There were no differences concerning the incidence of adverse events between the two groups. Therefore, the intake of ResistAid over a period of 12 weeks can be considered as safe as placebo."

ResistAid is a natural immune support ingredient extracted from North American larch trees, consisting of larch arabinogalactan and bioactive polyphenols. It has a number of technical properties, which make it formulation-friendly in applications such as dietary supplements and functional foods. ResistAid™ can be used in standalone form or combined with other products to increase functionality. It is self-affirmed GRAS with notification provided to the U.S. Food and Drug Administration.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.